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Introduction
The management of multimorbidity in older people 
is challenging. Treatment guidelines are generally 
derived from single disease trials which often exclude 
older participants, and their application to patients 
with multimorbidity may result in lengthy, problem-
atic prescriptions.1–4 While the individual recom-
mendations from a guideline may be rational, the 
sum of all recommendations for the individual mul-
timorbid patient is often inappropriate. In the United 
States, 39% of adults aged over 65 years take five or 
more daily medications.5 In Europe, almost 25% of 
nursing home residents take 10 or more daily medi-
cations.6 Polypharmacy, defined here as the concur-
rent use of five or more daily medications, may of 
course be appropriate and justified when treating 
multimorbid patients. However, polypharmacy, 
when it is inappropriate, is associated with a range of 
adverse consequences including falls, hip fractures, 
cognitive decline and avoidable hospitalizations.7–9 
Older people are particularly vulnerable to the harm-
ful effects of polypharmacy due to age-related 
changes in pharmacokinetics and pharmacodynam-
ics.10,11 Therefore, the challenge for the prescriber 
when treating older multimorbid patients is to strike 
a balance between optimizing chronic disease con-
trol and minimizing the risks of polypharmacy.
Inappropriate polypharmacy which engenders 
potentially inappropriate medications (PIMs) can be 
addressed by examining the process of prescribing.12 
This involves screening for inappropriate medication 
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use (IMU). IMU refers to (1) drug overuse, the use 
of drugs without a valid indication and (2) drug mis-
use, the incorrect choice of drug (potential harm 
outweighs the benefit, risk of drug–drug interactions 
or drug–disease interactions), incorrect dose or 
incorrect duration.12–14 The aim is to match the 
medication regimen to the patient’s overall condi-
tion and goals of care.15 Prescribers also have the 
opportunity to address inappropriate polypharmacy 
when they encounter the adverse outcomes of pre-
scribing. Adverse drug events (ADEs) cause or con-
tribute significantly to 6–17% of all hospital 
admissions in older adults.16,17 However, ADEs are 
under-recognized in this population because they 
commonly manifest as nonspecific symptoms such 
as fatigue, dizziness, falls, constipation and confu-
sion.11,18 It has been suggested that any new symp-
tom in an older patient should be considered a drug 
side effect until proven otherwise.18
Despite the importance of choosing the correct 
drugs, screening for IMU and recognizing ADEs, 
it is a fact that the great majority of older people 
with multimorbidity are managed by physicians 
who do not have expertise in geriatric medicine or 
pharmaco-therapeutics.19 Valid and effective 
methods are needed to assist these physicians 
with the management of patients with multimor-
bidity and polypharmacy.
In the last 30 years, multiple criteria-based strategies 
to address inappropriate polypharmacy have been 
published. Implicit PIM criteria are judgement-
based quality indicators that focus primarily on the 
patient rather than drugs or diseases. Although 
patient-centered and often sensitive for detection of 
IMU, this approach is time-consuming and very 
much depends on the knowledge and experience of 
the prescriber.12 For this reason, implicit criteria 
have limited applicability outside of the research set-
ting. In contrast, explicit criteria are clearly defined 
statements which highlight PIMs in particular clini-
cal circumstances. For the most part, explicit PIM 
criteria are based on trial evidence, expert opinion 
and consensus techniques.12 The intention is not to 
replace clinical judgement but rather to alert the 
prescriber to potential instances of IMU. There are 
currently 26 published explicit criteria-based tools 
to address inappropriate polypharmacy which have 
been described in recent reviews.20,21 The present 
review will focus primarily on the most widely used 
explicit, criteria-based PIM tools (Table 1) and, in 
particular, those that have been used as interven-
tions to address IMU in well-designed trials.
Beers criteria
Beers criteria are the most widely used criteria to 
evaluate potentially inappropriate prescribing in 
people over the age of 65 years. First published in 
1991, the criteria have been updated four times, 
the most recent iteration being published in 2015. 
Since 2011, the American Geriatrics Society 
(AGS) have taken responsibility to update and 
maintain the Beers criteria. The intention of the 
Beers criteria is to improve care of older adults by 
reducing IMU, reducing ADEs, educating physi-
cians and patients about appropriate pharmaco-
therapy, and by serving as a tool for evaluating 
quality of care, medication cost and patterns of 
drug use.22 The criteria are not designed to be 
used in a hospice or palliative care setting.
The 2015 AGS Beers criteria were developed fol-
lowing a systematic literature review and consen-
sus evaluation of evidence by a 13-member expert 
panel using a modified Delphi methodology.22 
The panel represented expertise in geriatric medi-
cine, nursing, clinical pharmacy, research and 
quality measures. For each criterion, a quality of 
evidence and strength of recommendation rating 
was assigned. In addition, the rationale behind 
each recommendation was explained. The final 
criteria included 88 medications or medication 
classes, which are divided into five categories:
(i).  drugs and drug classes to avoid in older 
adults independent of diagnosis or 
condition
(ii).  drugs and drug classes to avoid in older 
adults with certain diseases or syndromes
(iii).  drugs and drug classes that should be 
used with caution in older adults
(iv).  non-anti-infective drugs that should be 
avoided or adjusted in older adults with 
renal disease
(v).  non-anti-infective drug–drug interac-
tions that should be avoided in older 
adults.
The use of Beers criteria drugs in older people has 
been shown to be associated with an elevated risk 
of unplanned hospitalization in the United States, 
Australia and Taiwan.9,25–27 However, these find-
ings were not replicated in a European study and 
this may be explained by the fact that several 
drugs included in the Beers criteria are seldom 
prescribed or do not appear at all in drug formu-
laries in Europe.28,29 As a result, several country-
specific and region-specific derivations of Beers 
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Table 1. Most commonly used explicit criteria-based tools.
Criteria Validation 
method
Intended 
population
Organization of criteria Specific advantages Specific 
disadvantages
Beers 
criteria22
Delphi 
consensus; 
13 experts
Older people 
⩾65 years
(excluding 
people with 
palliative care 
needs)
88 drugs/drug classes in 
five categories:
1.  PIMs to be avoided for 
all older adults
2.  PIMs to be avoided 
in certain diseases/
syndromes
3.  PIMs to be used with 
caution
4.  PIMs to be avoided/
adjusted in patients 
with renal disease
5.  Drug–drug interactions 
to be avoided
Informed by extensive 
evidence review
Robust grading methodology
Concise
No RCT evidence 
of clinical benefit 
when used as an 
intervention.
Under-prescribing 
not addressed.
Alternative 
safer drugs not 
suggested.
STOPP/ 
START23
Delphi 
consensus; 
19 experts
Older people 
⩾65 years
STOPP: 80 criteria; START: 
34 criteria; organized 
according to physiological 
system
RCT evidence of clinical 
benefit when used as 
intervention compared with 
usual clinical care:
• reduction in IMU
• reduction in ADRs
•  reduction in 
polypharmacy and 
monthly medication cost
Alternative 
safer drugs not 
suggested.
EURO 
FORTA 
(‘Fit fOR 
The Aged’) 
list24
Delphi 
consensus; 
47 experts
Older people 
⩾65 years;
or ⩾60 years 
with ⩾6 
medications
264 drugs/drug classes 
organized into 26 categories 
according to diagnosis or 
clinical syndrome
RCT evidence of clinical 
benefit when used as 
intervention compared with 
usual clinical care:
•  reduced under-
prescribing
•  reduced overprescribing
•  reduced ADRs
•  improved functional 
scores
Prescriber is directed to use 
the safest/ most effective 
medications for common 
clinical scenarios.
Not validated 
outside of 
Germany.
Rationale behind 
grading for drugs 
not explained.
Drug–drug 
interactions and 
drug–disease 
interactions not 
addressed.
ADR, adverse drug reaction; IMU, inappropriate medication use; PIMs, potentially inappropriate medications; RCT, randomized controlled trial; 
START, Screening Tool to Alert doctors to the Right Treatment; STOPP, Screening Tool of Older Persons potentially inappropriate Prescriptions.
have recently been developed such as PRISCUS,30 
NORGEP31 and the EU(7)-PIM criteria.32 To 
date, there are no randomized controlled trials 
(RCTs) showing that application of the Beers cri-
teria (or its derivatives) to older people’s prescrip-
tions improves clinical outcomes.
STOPP/START criteria
The Screening Tool of Older Persons potentially 
inappropriate Prescriptions (STOPP) and the 
Screening Tool to Alert doctors to the Right 
Treatment (START) were developed in tandem 
in Ireland and published initially in 2008; the 
second iteration appeared in 2014.23,33 The 2014 
version was developed following an extensive lit-
erature review and two rounds of Delphi consen-
sus validation with 19 panellists across 13 
European countries, each with recognized exper-
tise in geriatric pharmacotherapy. STOPP ver-
sion 2 consists of 80 IMU criteria outlining 
clinical circumstances where specific, commonly 
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encountered medications or medication classes 
are considered potentially inappropriate in older 
people. Examples of these circumstances include:
(i).  Drugs prescribed without an evidence-
based indication for example, ‘levodopa 
or dopamine agonists for benign essential 
tremor.’
(ii).  Drugs prescribed beyond their recom-
mended duration for example, ‘proton 
pump inhibitors at full therapeutic dose 
to treat uncomplicated peptic ulcer dis-
ease beyond 8 weeks.’
(iii).  Drug–drug interactions for example, 
‘beta-blocker in combination with vera-
pamil or diltiazem (risk of heart block).’
(iv).  Drug–disease interactions for example, 
‘prochlorperazine or metoclopramide 
with Parkinsonism (risk of exacerbating 
Parkinsonian symptoms).’
(v).  Incorrect dosages for example, ‘long-
term aspirin at doses greater than 160 mg 
per day (increased risk of bleeding, no 
evidence for increased efficacy).’
The criteria are organized according to physiolog-
ical system and, in addition, there are sections 
relating to analgesic use, anticholinergic burden, 
and drugs that increase the risk of falls. START, 
comprised of 34 criteria, is designed to screen for 
potentially inappropriate under-prescribing and is 
intended to be used concomitantly with STOPP.
The use of STOPP/START to screen and address 
IMU in Europe, Asia, North America, South 
America, Africa and Australia suggests that the 
criteria have global relevance.34–41 In comparison 
with Beers criteria, patients with STOPP-defined 
IMU are more likely to have an ADE, present to 
the emergency department and be admitted to 
hospital.39
To date, STOPP/START criteria have been 
tested as an intervention in four RCTs. These tri-
als are summarized in Table 2. Gallagher and col-
leagues showed that, in older hospitalized 
patients, STOPP/START recommendations 
communicated to attending physicians at the time 
of hospital admission significantly improved med-
ication appropriateness compared with usual 
pharmaceutical care.42 In this RCT, medication 
appropriateness was measured using the medica-
tion appropriateness index (MAI) and the 
Assessment Of Underutilization (AOU), vali-
dated implicit IMU assessment tools.43,44 Using a 
similar design, O’Connor and colleagues showed 
that this intervention significantly reduced non-
trivial adverse drug reactions (ADRs) compared 
with usual pharmaceutical care (absolute risk 
reduction of 11.4%; number of patients needed 
to screen to prevent one ADR = 9).45 In Israel, 
Frankenthal and colleagues showed that applica-
tion of STOPP/START recommendations sig-
nificantly reduced polypharmacy (Table 3), IMU, 
incident falls and the average monthly cost of 
medications in frail elderly nursing home resi-
dents.46 Finally, in Belgium, Dalleur and col-
leagues applied STOPP criteria to the 
prescriptions of hospitalized older patients in 
addition to a comprehensive geriatric assessment 
(CGA).47 They showed that from this interven-
tion, the reduction in PIMs for the intervention 
group was double that for the control group at 
hospital discharge (39.7 and 19.3%, respectively; 
p = 0.013).However, there was no statistically 
significant difference between the intervention 
and control groups in the proportion of patients 
prescribed ⩾1 potentially inappropriate medica-
tion at the time of discharge from hospital (16.1% 
versus 23.1%). The more modest results in this 
trial may be explained by the fact that just 39.7% 
of STOPP/START recommendations were 
implemented. This is in contrast to the aforemen-
tioned trials where uptake of recommendations 
ranged between 82% and 91%. This is important 
because the success of STOPP/START criteria, 
or indeed any other explicit tool, as an interven-
tion will depend on its integration and implemen-
tation in normal clinical workflow.
Two multicenter European trials are currently 
underway which are designed to examine the clin-
ical impact of pharmacotherapy optimization 
software interventions based on STOPP/START 
version 2 criteria. SENATOR (‘Software Engine 
for the Assessment & Optimization of drug and 
nondrug Therapy in Older peRsons’) primarily 
examines the impact of the software intervention 
on ADR incidence in older people hospitalized 
with acute illness. A similar RCT called OPERAM 
(‘OPtimising thERapy to prevent Avoidable hos-
pital admissions in the Multimorbid elderly’) is 
focused on the effect of a different software sys-
tem on drug-related hospital admissions. The 
results of these trials are expected to be published 
in 2019 and 2020, respectively.
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FORTA (‘Fit fOR The Aged’) list
FORTA was initially proposed in 2008 by the 
German clinical pharmacologist, Professor 
Martin Wehling, and was validated for use in 
Germany and Austria through a two-round 
Delphi procedure involving 20 experts in 
2012.48,49 FORTA was updated in 2015 and, in 
subsequent years, six region-specific European 
FORTA lists were developed, validated and col-
lated into the EURO FORTA list.24 The EURO 
FORTA list consists of 264 medications/medica-
tion classes organized into 26 groups according to 
diagnosis or clinical syndrome. Each medication 
is graded according to the level of expected clini-
cal benefit to older patients:
A (Absolutely: indispensable, clear-cut 
benefit)
B (Beneficial: proven benefit but limited 
extent of effect or safety concerns)
C (Caution: questionable efficacy or safety 
profile; explore alternatives)
D (Don’t: avoid if possible; find alternative).
Guidance is given on the appropriateness of various 
drugs used to treat common conditions affecting 
older people such as hypertension, atrial fibrillation, 
chronic obstructive pulmonary disease, dementia, 
diabetes mellitus, idiopathic Parkinson’s disease 
and epilepsy. In addition, the drugs used to treat 
complex symptoms such as insomnia, behavioural 
and psychological symptoms of dementia and 
chronic pain are graded. The value of this format is 
that the prescriber is prompted to use the safest, 
most effective drugs first. Potentially harmful drugs 
are highlighted and, if required, the prescriber is 
directed towards more appropriate alternatives. 
However, important provisos are generally absent in 
the grading system. For example, opioids are 
assigned a grade B for the treatment of chronic pain. 
While undoubtedly effective, opioids are strongly 
associated with a range of potential adverse effects 
in older people including constipation and falls, and 
prescribers should be made aware of these well-
known potential side effects. In addition, anticoagu-
lants are assigned as grade A for use in the context 
of stroke prevention in older people. Routine anti-
coagulation for stroke is recommended only in cer-
tain specific clinical situations such as chronic atrial 
fibrillation and this grading, without extra qualifying 
information, has the potential to be misleading. 
Furthermore, drug–disease and drug–drug interac-
tions are not addressed in FORTA.
The 2012 FORTA list was evaluated in a rand-
omized controlled trial involving 409 hospitalized 
patients in Germany.50 Patients were cluster rand-
omized to the intervention or control group 
depending on which medical ward they were situ-
ated. Physicians overseeing the care of intervention 
Table 3. Impact of STOPP/START on inappropriate medication use and polypharmacy.
Study Pre-intervention: Post intervention
⩾1 PIMs
medications
Mean no. ⩾1 PIMs
medications
Mean no.
Gallagher and colleagues42 6 months  
Control patients 44.3% 8.0 50.6% 8.2
Intervention patients 43.2% 7.4 12.2% 7.7
Dalleur and colleagues47 Hospital discharge  
Control patients 51.4% – 41.9% –
Intervention patients 52.7% – 40.5% –
Frankenthal and colleagues46 1 year  
Control patients 32.4% 8.2 21.9% 8.9
Intervention patients 35.5% 8.8 6.3% 7.3
PIMs, potentially inappropriate medications; START, Screening Tool to Alert doctors to the Right Treatment; STOPP, 
Screening Tool of Older Persons potentially inappropriate Prescriptions.
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ward patients were provided with FORTA-based 
recommendations for each individual patient. The 
primary endpoint was the FORTA score, a bespoke 
quantitative measure of IMU based on the FORTA 
list, where higher scores indicated greater levels of 
IMU. Secondary outcomes included incident 
ADRs and functional status scores, with all out-
comes being measured at hospital discharge. In the 
intervention group, the median number of medica-
tions did not change between hospital admission 
and discharge. In contrast, the median number of 
daily medications in the control group increased by 
one. The primary endpoint (i.e. FORTA score) 
was significantly reduced (i.e. improved) in the 
intervention group relative to the control group. 
Intervention patients also had significantly reduced 
incidence of ADRs with a number needed to screen 
of only five to prevent one clinically significant 
ADR. Furthermore, significant improvements in 
functional scores were noted in the intervention 
group relative to the control group.
While these results are very encouraging, the trial 
had some significant limitations. The primary out-
come measure was derived from the intervention 
tool and the use of a separate, validated measure 
of medication appropriateness would have 
strengthened the clinical impact of the results. 
Furthermore, the proportion of patients who had 
at least one ADR was 52.3%. This ADR incidence 
is substantially higher than the ADR incidence 
reported in a number of recent studies which vary 
from 11.5% to 32.2%.44,51–54 ADRs were ascer-
tained using a trigger list of clinical events possibly 
representative of ADRs. These events included 
falls, confusion, nausea, dizziness, dyspnea, 
decompensated heart failure, acute kidney injury 
and angina. Dyspnea, not commonly defined as 
an ADR, accounted for almost 10% of all events. 
Of note, validated methods for assigning probabil-
ity of causation to a drug were not used. This is an 
important limitation because if the recorded 
events were not corroborated as true ADRs, then 
the reduced event rate reported in the intervention 
arm may be related to factors other than imple-
mentation of FORTA recommendations (e.g. 
ward-based falls prevention strategy, greater staff 
numbers in the intervention ward).
Conclusion
The complexity associated with multimorbidity 
and polypharmacy mandates a systematic 
approach to ensure the best possible patient 
outcomes. While ongoing education and training 
for prescribers is essential, it is not reasonable to 
expect all physicians who care for older people to 
have expertise in geriatric pharmacotherapy. 
Explicit tools simplify the process of medication 
optimization by alerting the prescriber to poten-
tial IMU in specific circumstances.
Ultimately, the goal of any IMU intervention tool 
is to improve medication appropriateness and 
minimize the risk of serious ADRs. The Beers cri-
teria, while groundbreaking in terms of being the 
first explicit criteria set to screen for IMU in older 
people, does not currently have a robust evidence 
base to support its use as an intervention tool. We 
contend that only explicit tools that have proven 
tangible clinical benefits merit serious attention. 
Currently, only STOPP/START criteria and the 
FORTA list meet this requirement on the basis of 
highly significant positive patient-related out-
comes in recent RCTs.
Recognition and prevention of IMU in the 
future must be evidence-based. That evidence 
base in turn depends on PIM detection and 
minimization strategies that are proven to work 
from RCT data. Explicit PIM criteria have 
found their way into routine clinical practice, 
unlike implicit PIM/IMU criteria which remain 
in the research domain. Explicit PIM criteria 
that have an RCT-proven clinical benefit need 
to be applied in the arena of routine medication 
review for multimorbid older people, in particu-
lar those who are exposed to the highest levels of 
polypharmacy and its associated ADRs and 
ADEs. The challenge facing busy prescribers 
everywhere is finding efficient and practical 
methods of PIM/IMU explicit criteria deploy-
ment in busy, routine clinical practice. 
Avoidance of unacceptably prolonged patient 
consultations resulting from medication review 
and application of explicit PIM/IMU criteria 
remains a significant practical and research 
challenge, the solutions to which clearly lie 
within the information and communications 
technology software domain.
Technological innovation will undoubtedly 
advance in the coming decades and widespread 
deployment of explicit criteria-based tools in daily 
clinical practice is likely to be realized through 
sophisticated, reliable software systems integrated 
into normal clinical workflows. We believe that 
clinically relevant, explicit recommendations 
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delivered to the prescriber in a timely manner, 
combined with emerging developments in phar-
macogenomics, offers one way to stem the tide of 
the inappropriate polypharmacy and associated 
ADRs and ADEs and to ensure optimal manage-
ment of the rapidly growing global population of 
multimorbid older patients.
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